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Do Not Pass Go, Do Not Stop for Summary 
Judgment: The U.S. District Court for the District 
of Delaware’s Seemingly Disjunctive Yet Efficient 
Procedures in Hatch-Waxman Litigation 
By Katherine Rhoades* 
ABSTRACT 
 With the multi-billion dollar generic pharmaceutical industry growing annually, 
litigation under the Hatch-Waxman Act—the legislation that expedited the Food & Drug 
Administration’s (“FDA”) approval process for generic drugs—can have substantial 
economic implications on American consumers.  Under the Hatch-Waxman Act, a generic 
drug company can challenge a brand-name pharmaceutical company’s pioneer drug 
patent(s) in an Abbreviated New Drug Application (“ANDA”) by filing a Paragraph IV 
certification with the FDA, and the patentee can—and usually does—sue for infringement.  
The court may find the pioneer drug patent(s) invalid or not infringed by the generic drug, 
which results in savings to American consumers when the affordable generic drug is 
eventually brought to market.  The United States District Court for the District of 
Delaware’s four Article III judges hear the majority of cases arising under the Hatch-
Waxman Act.  However, unlike other patent-heavy dockets, the District of Delaware does 
not have uniform local patent rules and very rarely entertains motions for summary 
judgment in Hatch-Waxman litigation.  This article evaluated the District of Delaware’s 
procedures in handling Hatch-Waxman cases and presents an empirical study of the 
district’s summary judgment practice in these cases.  The empirical study shows that the 
District of Delaware’s practice is efficient and predictable and not contrary to the purpose 
behind the Hatch-Waxman Act: to bring more low-cost generic drugs to consumers.  
Because the district has a bench experienced in patent litigation, the District of Delaware 
does not need to adopt local patent rules and should continue its current practice of rarely 
hearing summary judgment motions in ANDA cases. 
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¶1  The United States pharmaceutical industry is a multi-billion dollar industry that 
continues to grow.  Generic drug companies make up a large part of the pharmaceutical 
market, accounting for roughly seventy-one percent of the prescription drugs purchased 
annually.1  Many Americans rely on these low-cost alternatives to brand-name drugs, but 
this booming industry did not always exist.  The prior lengthy and expensive Food & Drug 
Administration (“FDA”) approval regime for pharmaceutical drugs left little incentive for 
generic drug manufacturers to seek FDA approval.  This resulted in few low-cost 
alternatives for Americans unhappy with costly brand-name drug prices. 
¶2  Congress sought to increase the availability of low-cost generic drugs to consumers.  
In September 1984, Congress created a streamlined approval process for generic drugs by 
passing the Drug Price Competition and Patent Term Restoration Act of 1984, which 
launched a new era in the generic drug industry.2  This landmark legislation, commonly 
known as the Hatch-Waxman Act, allows a generic drug manufacturer (“generic”) to file 
an Abbreviated New Drug Application (“ANDA”) with the FDA, which significantly 
expedited the process to get the FDA approval necessary for bringing many generic drugs 
to the market.  Congress sought to strike a balance between generics and innovators with 
this new legislation.  Along with the expedited approval process for generics, the Hatch-
Waxman Act also provided additional incentives to innovators such as a patent term 
extension and restrictions on the generic drugs eligible for the ANDA process.3  For 
example, the Hatch-Waxman Act does not allow generics to place generic equivalents of 
patented drugs on the market, and owners of valid pharmaceutical patents can seek recourse 
in federal court under the Hatch-Waxman Act.4  
¶3  The United States District Court for the District of Delaware and the United States 
District Court for the District of New Jersey are overwhelmingly the favored jurisdictions 
of brand-name pharmaceutical companies seeking to enjoin generics from placing their 
allegedly infringing generic drugs on the market under the Hatch-Waxman Act.5  This is 
due in part to the high number of drug companies headquartered or incorporated in 
Delaware or New Jersey.  The local rules and local practice governing ANDA cases in 
these two districts vary significantly.  Hatch-Waxman litigation in the District of Delaware 
can be described as “courtroom-specific”; that is, the local rules and procedures vary 
noticeably among its four Article III judges.6  In comparison, the District of New Jersey 
 
1 Somnath Pal, Shifts in the Generic-Drug Market: Trends and Causes, U.S. PHARMACIST (June 21, 
2013), http://www.uspharmacist.com/content/s/253/c/41309/ [https://perma.cc/QZY3-YEUP]. 
2 See Drug Price Competition and Patent Term Restoration Act of 1984 § 101, 21 U.S.C. § 355(j) 
(1984). 
3 See id. § 201, 35 U.S.C. § 156 (1984); id. § 101. 
4 See id. § 202, 35 U.S.C. § 271(e). 
5 Kevin E. Noonan, Lex Machina Looks at ANDA Cases, PATENT DOCS (Nov. 5, 2014), 
http://www.patentdocs.org/2014/11/lex-machina-looks-at-anda-cases.html [https://perma.cc/RPM7-X5JR]; 
Brian C. Howard, 2014 Patent Litigation Year in Review, LEX MACHINA 1, 13 (Mar. 26, 2015), 
http://pages.lexmachina.com/rs/lexmachina/images/2014 Patent Litigation Report.pdf 
[https://perma.cc/T2ZR-D7Y7] (“ANDA litigation is heavily concentrated in the Districts of New Jersey 
and Delaware.”).  The most litigation occurs in the District of Delaware, followed by the District of New 
Jersey.  Noonan, supra note 5.  
6 See Judges’ Info, U.S. DISTRICT. CT. DISTRICT. DEL., http://www.ded.uscourts.gov/judges-info 
[https://perma.cc/6SXT-W2JQ]. 




has adopted uniform local patent rules with Hatch-Waxman-specific provisions that govern 
all ANDA cases in the district, regardless of which of its twenty-five Article III judges 
presides over the case.7  Additionally, Delaware’s judges seldom allow ANDA litigants to 
bring motions for summary judgment. 
¶4  The Hatch-Waxman Act seeks to accelerate the process of bringing low-cost generic 
drugs to consumers.  This article explores some of the District of Delaware’s practices and 
procedures in handling ANDA cases to see whether those practices frustrate the purpose 
behind the Hatch-Waxman Act by delaying the release of these low-cost drugs to the 
market.  Part I presents the important provisions of the Hatch-Waxman Act that give rise 
to ANDA litigation, as well as the policies behind the Act.  Part II explores the local rules 
and local practice in the District of Delaware and compares it with the District of New 
Jersey.  This article focuses specifically on the District of Delaware but references the 
District of New Jersey’s local rules and procedures to contrast with Delaware.  Part III 
presents an empirical study of summary judgment motion practice in ANDA cases in those 
two districts.  Part IV concludes that while the District of Delaware’s local rules and 
procedures may seem disjunctive and inefficient at first glance, the district does not need 
uniform local patent rules because the judges are extremely experienced and efficient in 
handling patent cases, and of most relevance, in ANDA cases.  However, Part IV further 
explains that the District of Delaware could improve its handling of ANDA cases by 
requiring early disclosure of the ANDA in litigation.    
I. BACKGROUND OF THE HATCH-WAXMAN ACT 
¶5  The Hatch-Waxman Act amended the Federal Food, Drug, and Cosmetic Act, and  
“effectively created the modern generic pharmaceutical industry.”8  By enacting the Hatch-
Waxman Act, Congress provided the FDA with a new complex regulatory scheme to 
govern the approval of generic drugs.9  The approval process allows generics to get their 
lower-cost alternatives on the market more quickly than under the previous FDA regime. 
 
7 See D.N.J. L. CIV. R. App. T.  In 2011, New Jersey was selected to participate in the congressionally 
enacted Patent Pilot Program, see Pilot Program in Certain District Courts, Pub. L. No. 111-349 § 1, 124 
Stat. 3674 (2011), and has adopted procedures for the allocation of patent cases in its district, see D.N.J. L. 
CIV. R. 40.1(f); D.N.J. L. PAT. R. 1.5.  Delaware was not selected to participate in the pilot program.  See 
Ron Vogel, The Patent Pilot Program: Reassignment Rates and the Effect of Local Patent Rules, NYIPLA 
13, 13 (Oct./Nov. 2013), http://www.fr.com/files/Uploads/Documents/Vogel.NYIPLABulletin.Pilot-Patent-
Program-Reassignment-Rates-and-Effects-of-Local-Rules.OctNov2013.pdf [https://perma.cc/BY2J-B45B].  
The Patent Pilot Program allows judges to transfer patent cases on their docket to a judge in the district who 
has opted to participate in the program.  See id.  “Delaware was the only patent-intense district not included 
in the Program.”  Id.  Since Delaware has only four Article III judges, its non-participation in the program 
is not unusual. 
8 Matthew Avery, Continuing Abuse of the Hatch-Waxman Act by Pharmaceutical Patent Holders and 
the Failure of the 2003 Amendments, 60 HASTINGS L.J. 171, 175 (2008). 
9 Colleen Kelly, The Balance Between Innovation and Competition: The Hatch-Waxman Act, the 2003 
Amendments, and Beyond, 66 FOOD & DRUG L.J. 417, 417 (2011). 
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A. ANDA Approval Process 
¶6  Under the Hatch-Waxman Act, a generic seeking FDA approval of its drug may file 
an ANDA with the FDA10 rather than a New Drug Application (“NDA”).11  In comparison, 
before a research-based pharmaceutical company can market its pioneer drug, it must 
submit an NDA containing extensive pre-clinical and clinical data establishing the drug’s 
safety and efficacy.12  Before the Hatch-Waxman Act, a generic seeking FDA approval 
had to submit an NDA.  This meant that if an NDA submitted by the pioneer 
pharmaceutical company of the same drug had already been approved, the FDA still 
required the generic to file a lengthy NDA containing clinical data of the generic version 
of the approved drug even though the FDA had already concluded that the drug was safe 
and effective by approving the first NDA.13  This regulatory system slowed the 
development of marketable generic equivalents.14  Under the current system, rather than 
requiring the generic to submit full clinicals on safety and efficacy of the generic drug, the 
Hatch-Waxman Act instead requires that a generic submit an ANDA containing scientific 
data showing that the drug is the “bioequivalent”15 of a drug approved in an NDA.16   
¶7  The Hatch-Waxman regulatory scheme ensures that generic drugs meet FDA quality 
standards, while simplifying the generic drug approval process.  This encourages the 
development of generic drugs, thereby accelerating consumer access to these affordable 
drugs.17  An ANDA applicant can rely entirely on the pioneer pharmaceutical company’s 
lengthy and costly clinical data provided in the approved NDA and has no obligation to 
provide the FDA with its own proof of safety and efficacy as long as the generic can prove 
bioequivalency.18   
 
10 21 U.S.C. § 355(j) (2015). 
11 Id. § 355(a). 
12 See Avery, supra note 8, at 174–75 (discussing the extensive testing and analysis pharmaceutical 
companies perform in order to prove the drug’s safety and efficacy in an NDA). 
13 Id.  
14 See id.  In fact, “just before the Hatch-Waxman Act was passed, the FDA estimated there were 
approximately 150 brand-name drugs on the market with expired patents but no generic equivalents.”  Id.   
15 Under the Hatch-Waxman Act: 
A drug shall be considered to be bioequivalent to a listed drug if— 
(i) the rate and extent of absorption of the drug do not show a significant difference from the rate and 
extent of absorption of the listed drug when administered at the same molar dose of the therapeutic 
ingredient under similar experimental conditions in either a single dose or multiple doses; or 
(ii) the extent of absorption of the drug does not show a significant difference from the extent of 
absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient 
under similar experimental conditions in either a single dose or multiple doses and the difference from 
the listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is 
not essential to the attainment of effective body drug concentrations on chronic use, and is considered 
medically insignificant for the drug.  
21 U.S.C. § 355(j)(8)(B). 
16 Kelly, supra note 9, at 417.  When filing an ANDA with the FDA, a generic need only “demonstrate 
that its generic drug has the same active ingredient, the same basic pharmacokinetics, and is bioequivalent 
to the pioneer drug.”  Avery, supra note 8, at 176; see 21 U.S.C. § 355(j)(2)(A)(ii)–(iv).  This does not 
suggest that the generic need only prove bioequivalency in its ANDA.  A generic must submit a variety of 
information to the FDA in its ANDA, including chemistry manufacturing and controls.  See 21 U.S.C. § 
355(j)(b)(2)(A)(vi).  Therefore, while the amount of information submitted in an ANDA is substantially 
less than an NDA, there is still some meat to an ANDA.    
17 Avery, supra note 8, at 176. 
18 Id.; see Janssen Pharmaceutica, N.V. v. Apotex, Inc., 540 F.3d 1353, 1356 (Fed. Cir. 2008) (“Generic 




¶8  This eliminates duplicative research and clinical trial costs previously required of 
generics.19 
¶9  Even if a generic proves that its generic drug is the “bioequivalent” of a drug 
approved in an NDA, there are limits to the FDA’s approval power.  The FDA cannot 
approve an ANDA for a generic drug that will infringe a valid patent.20  When filing an 
ANDA, the generic must certify that the drug it seeks to market is (I) not patented, (II) the 
patent has expired, (III) the generic drug will not go on the market until the patent expires, 
or (IV) the “patent is invalid or will not be infringed by the manufacture, use, or sale of the 
[generic] drug . . . .”21  These are referred to as Paragraph I, II, III, and IV certifications 
respectively.  By filing a Paragraph IV certification, a generic seeks to market an equivalent 
of a patented drug before the patent has expired when it believes the patent is invalid, not 
infringed, or unenforceable.22  But the Hatch-Waxman Act prohibits the FDA from 
approving an ANDA “until all patent protection and market exclusivity periods have 
expired.”23 
¶10  Once the FDA approves an ANDA containing a Paragraph IV certification, the 
generic receives 180-day marketing exclusivity for its approved generic drug.24  The 
exclusivity period seeks to encourage and reward the first Paragraph IV challenger “for 
undertaking the costs and risks of patent litigation” in filing an ANDA challenging the 
validity of the patent.25  Thus, a successful Paragraph IV challenger is given six months to 
market its generic drug without any generic competition.26 
B. Purpose and Policy of the Hatch-Waxman Act 
¶11  The Hatch-Waxman Act was designed as a compromise between competing policy 
objectives.27  One the one hand, Congress sought to increase the availability of low cost, 
 
drug companies are not required to conduct their own independent clinical trials to prove safety and 
efficacy, but can instead rely on the research of the pioneer pharmaceutical companies.”). 
19 See Avery, supra note 8, at 176.  And by not requiring generics to undertake duplicative clinical trials, 
the Act allows for safe, previously patented generic drug equivalents to reach consumers, while saving 
Americans billions of dollars.  See Kelly, supra note 9, at 426. 
20 See 21 U.S.C. § 355(j)(2)(A)(vii)(I)–(IV). 
21 Id.  
22 Michael R. Herman, The Stay Dilemma: Examining Brand and Generic Incentives for Delaying the 
Resolution of Pharmaceutical Patent Litigation, 111 COLUM. L. REV. 1788, 1795 (2011). 
23 Kelly, supra note 9, at 418.  By including this requirement, Congress sought to encourage generics to 
challenge stale patents on the market, while also giving valid patents the utmost protection to encourage 
innovation.  See Janssen Pharmaceutica, 540 F.3d at 1355–56. 
24 21 U.S.C. § 355(j)(5)(B)(iv). 
25 Avery, supra note 8, at 178 (quoting Representative Henry Waxman, Speech at the Generic 
Pharmaceutical Association’s First Annual Policy Conference: Securing the Future of Affordable Medicine 
(Sept. 20, 2005)). 
26 Avery, supra note 8, at 178.  This period may be cut short.  For example, the “180-day exclusivity can 
begin to run—with a court decision—even before an applicant has received approval for its ANDA.  In that 
case, some, or all of the 180-day period, could expire without the ANDA applicant marketing its generic 
drug.”  FTC Study: Generic Drug Entry Prior to Patent Expiration: Before the Senate Committee on the 
Judiciary (2003) (statement of Daniel E. Troy, Chief Counsel, FDA), 
http://www.fda.gov/NewsEvents/Testimony/ucm161034.htm [https://perma.cc/2QSW-ZCKQ]. 
27 See aaiPharma Inc. v. Thompson, 296 F.3d 227, 230 (4th Cir. 2002) (citations and internal quotation 
marks and omitted) (discussing how the Hatch-Waxman Act was an “effort to strike a balancing between 
two conflicting policy objectives”). 
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generic drugs for American consumers.28  On the other hand, in doing so, Congress did not 
want to discourage research-based pharmaceutical companies from investing in the 
research and development of new drugs.29  Legislators wanted to continue to incentivize 
pharmaceutical companies to research and invent new drugs to treat medical conditions.30  
To achieve these objectives, Congress created the ANDA approval process for non-
infringing generic drugs to increase competition among generics and research-based 
pharmaceutical drug companies, as well as competition between generics, thereby lowering 
costs to consumers.31  Additionally, to provide incentives for research-based 
pharmaceutical companies to continue invest in research and development, the Hatch-
Waxman Act included “patent term extensions of up to five years to compensate for 
marketing delays during the regulatory review period prior to the first permitted 
commercial marketing of a new drug.”32    
C. Paragraph IV Certifications  
¶12  Litigation frequently arises under the Hatch-Waxman Act.  Hatch-Waxman litigation 
arises when a generic files an ANDA with the FDA containing a “[P]aragraph IV 
certification challenging a brand drug manufacturer’s patent(s)”.33  Filing an ANDA with 
a Paragraph IV certification is itself an act of patent infringement.34  Therefore, the Hatch-
Waxman Act requires all Paragraph IV ANDA filers to provide notice to the challenged 
patent holder (“patentee”), which should “include a detailed statement of the factual and 
legal basis” of why the applicant believes “that the patent is invalid or will not be 
infringed.”35  Upon receipt of the notice, the patent holder can bring an infringement action 
against the ANDA applicant within forty-five days.36  However, if the patent holder fails 
to file a suit within that time, “the approval [of the ANDA] shall be made effective 
immediately” upon the FDA’s completion of substantive review of the ANDA.37 
 
28 See H.R. REP. NO. 98–857, pt. 1, at 14 (1984) (“The purpose of Title I of the bill is to make available 
more low cost generic drugs by establishing a generic drug approval procedure for pioneer drugs first 
approved after 1962.”); Avery, supra note 8, at 172 (noting that such a balance of rights is necessary to 
prevent pharmaceutical pioneers from reaping “monopoly profits indefinitely”). 
29 Kelly, supra note 9, at 417; see Avery, supra note 8, at 171 (noting that “[t]he pharmaceutical industry 
is one of the few industries that requires patent protection to ensure the profitability of its innovative 
products” due to the enormous costs that companies must sink into research and development).  
30 Kelly, supra note 9, at 417.   
31 Id. 
32 Rebecca S. Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH. TELECOMM. & TECH. L. 
REV. 345, 357–58 (2007); see Drug Price Competition and Patent Term Restoration Act of 1984 § 201, 35 
U.S.C. § 156 (1984). 
33 2014 Patent Litigation Study, PRICEWATERHOUSECOOPERS 1, 20 (2014), 
http://www.pwc.com/en_US/us/forensic-services/publications/assets/2014-patent-litigation-study.pdf 
[https://perma.cc/PP35-S5ZF]. 
34 See 35 U.S.C. § 271(e)(2)(A) (2015) (“It shall be an act of infringement to submit . . . [an ANDA] for 
a drug claimed in a patent or the use of which is claimed in a patent . . . .”). 
35 21 U.S.C. § 355(j)(2)(B)(iv)(II). 
36 Id. § 355(j)(5)(B)(iii); see also 35 U.S.C. § 271(e)(5) (allowing a generic to bring a declaratory 
judgment action against the patentee if the patentee fails to bring an infringement action within the forty-
five day period). 
37 21 U.S.C. § 355(j)(5)(B)(iii).  While the statute uses the “immediately” language, it is a bit 
misleading.  If no suit is filed within forty-five days, that does not mean that the ANDA will be approved 
on day forty-six.  It may take years for the FDA to complete its substantive review of the ANDA. 




¶13  If the patent holder does assert its patent against the ANDA filer within the forty-five 
day time period, it automatically triggers a thirty-month stay.38  During the thirty-month 
stay, “the FDA is barred from approving the ANDA” but may tentatively approve the 
application, which “become[s] effective immediately upon expiration of the stay.”39  The 
stay is intended to protect patent holders with valid drug patents,40 but if the patent expires 
or if a district court finds the patent invalid or not infringed by the ANDA, the FDA can 
immediately approve the ANDA before expiration of the thirty-month stay.41 
¶14  The litigation between patentees and ANDA filers are bench trials that rarely award 
damages.42  Damages are rare in these suits because the alleged infringer has not put the 
drug on the market yet, and thus, usually has not made any infringing sales prior to the 
suit.43  Instead, patentees seek injunctive relief from the court to prevent a generic from 
putting their drug on the market.44  Because patentees risk losing patent protection on their 
highly profitable brand-name drugs, the potential economic implications of ANDA 
litigation are significant. 
II. LOCAL RULES AND SUMMARY JUDGMENT PRACTICE IN THE DISTRICT 
OF DELAWARE  
¶15  At first glance, in comparing the two most favored ANDA litigation districts, the 
District of Delaware’s rules and procedures in handling ANDA cases appear disjunctive 
and inefficient compared to the District of New Jersey’s rules and practice.  ANDA 
litigation has grown substantially in the past decade, and Delaware and New Jersey are the 
most active districts for ANDA litigation by far.45  These two districts combined have 
handed down almost half of all ANDA court decisions since 1995,46 which is not surprising 
since these districts are home to many pharmaceutical companies.  However, the local court 
rules governing ANDA cases in the District of Delaware and the District of New Jersey 
are significantly different.  Also, the local procedures in ANDA cases, specifically 
summary judgment practice, differ considerably between these two districts.  While this 
article focuses specifically on ANDA litigation in the District of Delaware, New Jersey’s 
local rules and practice are referred to for comparison.  It is worth comparing the districts’ 
procedures in handling ANDA cases to evaluate whether the District of Delaware’s rules 
and practice are efficient in furthering the objectives of the Hatch-Waxman Act.   
 
38 See id. 
39 Avery, supra note 8, at 177; see 21 U.S.C. § 355(j)(5)(B)(iv)(II)(dd). 
40 Avery, supra note 8, at 177. 
41 See 21 U.S.C. § 355(j)(5)(B)(iii)(I)–(II). 
42 See Brian D. Coggio et al., The Right to a Jury Trial in Actions Under the Hatch-Waxman Act, 79 J. 
PAT. & TRADEMARK OFF. SOC’Y 765, 767 (1997). 
43 See id. 
44 See id.; see 35 U.S.C. § 271(e)(4). 
45 Noonan, supra note 5; see Howard, supra note 5, at 13; 2013 Patent Litigation Study, 
PRICEWATERHOUSECOOPERS 1, 28 (2013), http://www.pwc.com/en_US/us/forensic-
services/publications/assets/2013-patent-litigation-study.pdf [https://perma.cc/7N4E-SA88].  The “most 
ANDA litigation occurs in the District of Delaware (678 cases),” followed by “the District of New Jersey 
(481 cases) . . . .”  Noonan, supra note 5. 
46 See 2013 Patent Litigation Study, supra note 45, at 28; see also Noonan, supra note 5.  Since 1995, 
there have been 137 ANDA court decisions, and sixty-two of those decisions were handed down by judges 
in Delaware or New Jersey.  2013 Patent Litigation Study, supra note 45, at 28 
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A. The Local Rules: Delaware vs. New Jersey 
¶16  Over the last decade, patent rules have become an integral part of patent litigation.47  
At least twenty-four U.S. district courts have formally adopted local patent rules to govern 
patent litigation.48  The District of New Jersey is one of those many districts.49  The District 
of New Jersey has also amended its local patent rules to include unique disclosure 
provisions exclusive to patent cases arising under the Hatch-Waxman Act.50  The District 
of Delaware has not followed suit.  Delaware has adopted neither rules to govern Hatch-
Waxman cases nor any local patent rules.51  New Jersey’s bench has twenty-five Article 
III judges52 while the District of Delaware has four.53  The purpose of local patent rules is 
to increase predictability and efficiency by promoting uniformity among the district,54 so 
uniform local patent rules may be more important in districts with more district court 
judges, such as the District of New Jersey.  However, like several other districts, the District 
of Delaware’s individual judges do have standing orders similar to local patent rules.55 
B. The District of Delaware’s Local Rules  
¶17  The District of Delaware’s local rules differ significantly from the District of New 
Jersey’s local patent rules and Hatch-Waxman provisions.  Most apparent is the fact that 
Delaware has not adopted local patent rules, let alone Hatch-Waxman provisions.56  In fact, 
among its Local Civil Rules, Delaware has only one rule specifically directed at patent 
cases.57   
 
47 See Travis Jensen, Basics, LOCAL PATENT RULES, http://www.localpatentrules.com/basics/ (last 
visited Mar. 5, 2016) [https://perma.cc/J799-E4YB].  The Northern District of California was the first to 
adopt local patent rules in 2001.  Arthur Gollwitzer III, Local Patent Rules—Certainty and Efficiency or a 
Crazy Quilt of Substantive Law?, 13 ENGAGE: J. FEDERALIST SOC’Y PRAC. GROUPS 94, 94 (2012). 
48 Gollwitzer, supra note 47, at 94; see generally D.N.J. L. PAT. R.; E.D. TEX. P.R.; N.D. ILL. LPR.  
District courts have authority to adopt local patent rules under Federal Rule of Civil Procedure 83.  
Gollwitzer, supra note 47, at 95; see FED. R. CIV. P. 83. 
49 See generally D.N.J. L. PAT. R.  These rules govern all civil actions “which allege infringement of a 
patent in a complaint, counterclaim, cross-claim or third party claim, or which seek a declaratory judgment 
that a patent is not infringed, is invalid or is unenforceable.”  D.N.J. L. PAT. R. 1.2. 
50 See D.N.J. L. PAT. R. 3.6 (“Disclosure Requirements for Patent Cases Arising Under 21 U.S.C. § 355 
(commonly referred to as “the Hatch-Waxman Act”)). 
51 See generally D. DEL. LR. 
52 At the time this article was written, the District of New Jersey had fourteen active Article III judges, 
eight Article III judges with senior status, and three judicial vacancies.  United States District Court for the 
District of New Jersey, BALLOTPEDIA, 
https://ballotpedia.org/United_States_District_Court_for_the_District_of_New_Jersey (last visited Feb. 26, 
2016) [https://perma.cc/LYC3-JK77]; see Our Judges, U.S. DISTRICT CT. DISTRICT N.J., 
http://www.njd.uscourts.gov/our-judges (last visited Feb. 26, 2016) [https://perma.cc/Y7HY-TRGV]. 
53 Judges’ Info, U.S. DISTRICT CT. DISTRICT DEL., http://www.ded.uscourts.gov/judges-info (last visited 
Mar. 9, 2016) [https://perma.cc/VV2R-WVE7]. 
54 See Gollwitzer, supra note 47, at 94.  With more judges, there is more potential for variation between 
judges.   
55 See Jensen, supra note 47; see e.g., Standing Orders, U.S. DISTRICT CT. DISTRICT DEL., 
http://www.ded.uscourts.gov/court-info/local-rules-and-orders/general-orders (last visited Mar. 9, 2016) 
[https://perma.cc/7TA4-9VVN]. 
56 See generally, D. DEL. LR.  
57 See D. DEL. LR 3.2 (“In all patent cases, copies of the patents at issue shall be attached and filed with 
the complaint.”). 




1. Delaware’s ANDA Procedures and Its Judges’ Idiosyncrasies  
¶18  Since the District of Delaware has not adopted local patent rules, the procedures 
governing ANDA cases in Delaware are “courtroom specific.”  The District of Delaware 
has one division, and its bench comprises only four Article III judges—Chief Judge 
Leonard P. Stark, Judge Sue L. Robinson, Judge Gregory M. Sleet, and Judge Richard G. 
Andrews.58  While Delaware has not adopted local patent rules, its individual judges have 
standing orders and guidelines that operate in effect like local patent rules.59  However, 
unlike uniform local patent rules, the standing orders and guidelines are specific to the 
individual judge.60  For example, each judge has his or her own model scheduling order 
for patent cases that sets out his or her general default procedures.61  But the pertinent 
procedures for each judge vary considerably, and thus, the procedures governing ANDA 
cases in Delaware depend on to whose courtroom the parties are assigned. 
¶19  In June 2014, Chief Judge Leonard P. Stark implemented new patent procedures for 
handling patent cases in his courtroom.62  Those revised procedures include provisions 
governing almost all aspects of litigation, including: discovery, scheduling and case 
management, motions, invalidity and infringement contentions, Markman hearings,63 
summary judgment, Daubert motions,64 pretrial orders, and trial.65  However, these patent 
procedures govern only “all non-ANDA patent cases” assigned to Chief Judge Stark.66  The 
Chief Judge also has two different scheduling orders for patent cases: (1) Patent Scheduling 
 
58 See Comparison of the Most Popular Patent Venues, LAW360 (Dec. 10, 2009), 
http://www.cooley.com/files/Law360.Patent Venue Article. Mitchell.Tilly.pdf [https://perma.cc/9FUA-
FVUT]; see also Judges Info, supra note 53.  
59 See Standing Orders, supra note 55.  Each judge also has procedures and guidelines to govern patent 
cases in their courtroom that they post on their individual pages on the district’s website.  See also Judges 
Info, supra note 53. 
60 See Judges Info, supra note 53. 
61 See e.g., Revised Patent Form Scheduling Order (ANDA), U.S. DISTRICT CT. DISTRICT DEL. (July 1, 
2014), http://www.ded.uscourts.gov/sites/default/files/Chambers/LPS/PatentProcs/LPS-PatentSchedOrder-
ANDA.pdf [https://perma.cc/22VY-FAVX] [hereinafter Chief J. Stark’s ANDA Patent Scheduling Order]; 
Patent Case Scheduling Order, U.S. DISTRICT CT. DISTRICT DEL. (Feb. 5, 2015), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Forms/Sched-Order-Patent2-05-15.pdf 
[https://perma.cc/228C-TU3N] [hereinafter J. Robinson’s Patent Scheduling Order]. 
62 See Honorable Leonard P. Stark, Revised Procedures for Managing Patent Cases, U.S. DISTRICT CT. 
DISTRICT DEL. 1, 1 (June 18, 2014), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/LPS/PatentProcs/LPS-PatentProcedures.pdf 
[https://perma.cc/5WQW-XCJG] [hereinafter Chief J. Stark’s Patent Procedures]. 
63 In Markman v. Westview Instruments, Inc., the U.S. Supreme Court held that in patent cases, the issue 
of claim construction is a matter of law reserved for the district court judge, not the jury.  517 U.S. 370, 
388–89 (1996).  The Supreme Court recently reaffirmed this aspect of Markman.  See Teva Pharm. v. 
Sandoz, Inc., 135 S. Ct. 831, 835 (2015).  Thus, judges now hold a pretrial claim construction hearing, or a 
“Markman hearing,” to hear the parties’ arguments on how to construe the claims in the asserted patent.  
Frank M. Gasparo, Markman v. Westview Instruments, Inc. and its Procedural Shock Wave: The Markman 
Hearing, 5 J.L. & POL’Y 723, 724–25 (1997).  
64 Trial judges, including those presiding over ANDA cases, are charged with the task of acting as 
gatekeepers to expert testimony and must determine the reliability and relevance of an expert’s testimony 
before it is admissible.  See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 597 (1993).  Parties can 
seek to exclude unreliable expert testimony by filing a pretrial motion known as a “Daubert motion.”  See 
Andrew Jurs, Gatekeeper with a Gavel: A Survey Evaluating Judicial Management of Challenges to Expert 
Reliability and Their Relationship to Summary Judgment, 83 Miss. L.J. 325, 326 (2014).  
65 See generally Chief J. Stark’s Patent Procedures, supra note 62. 
66 Id. at 1 (emphasis in original). 
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Order (non-ANDA)67 and (2) Patent Scheduling Order (ANDA).68  The non-ANDA patent 
scheduling order contains a section for Chief Judge Stark to set a deadline for all case 
dispositive motions, such as motions for summary judgment.69  In comparison, his ANDA 
patent scheduling order states: “[a]bsent agreement between the parties, the Court will 
generally not hear case dispositive motions in ANDA cases.”70  
¶20  Unlike Chief Judge Stark, Judge Sue L. Robinson has only one patent case 
scheduling order, which appears to apply to ANDA cases as well as non-ANDA.71  Judge 
Robinson’s patent scheduling order allows parties to file summary judgment motions with 
no explicit constraint on parties to ANDA cases.72  Judge Robinson also provides patent 
litigants with certain guidelines that govern her courtroom; but again, she makes no 
distinction between normal patent cases and ANDA cases.73  For example, she permits 
each party to file “one motion relating to infringement and one motion relating to 
validity.”74   
¶21  Judge Gregory M. Sleet has implemented his own procedural rules to govern his 
courtroom as well.  Like Judge Robinson, he has only one scheduling order to govern all 
patent cases.75  However, his scheduling order requires that “[p]rior to filing any summary 
judgment motion, the parties must submit letter briefs seeking permission to file the 
motion.”76  Also unique to Judge Sleet are his patent standing orders, which provide for 
appointment of “special masters” to hear discovery disputes in patent cases.77  
 
67 Revised Patent Form Scheduling Order, U.S. DISTRICT CT. DISTRICT DEL. (June 2014), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/LPS/PatentProcs/LPS-PatentSchedOrder-Non-
ANDA.pdf [https://perma.cc/65QV-DY7U] [hereinafter Chief J. Stark’s non-ANDA Patent Scheduling 
Order]. 
68 Chief J. Stark’s ANDA Patent Scheduling Order, supra note 61.  
69 See Chief J. Stark’s non-ANDA Patent Scheduling Order, supra note 67, at 11. 
70 Chief J. Stark’s ANDA Patent Scheduling Order, supra note 61, at 10. 
71 See J. Robinson’s Patent Scheduling Order, supra note 61. 
72 See id. 
73 See, e.g., Additional Civil Trial Guidelines for Patent Cases, U.S. DISTRICT CT. DISTRICT DEL. (Dec. 
21, 2010), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Misc/Additional_Civil_Trial_Guidelines-
Patent_Cases_12-21-10.pdf [https://perma.cc/FA69-WR6W] [hereinafter J. Robinson’s Additional 
Guidelines]; Briefing Guidelines in Complex Cases, U.S. DISTRICT CT. DISTRICT DEL. (Dec. 3, 2013), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Misc/Briefing_Guidelines-Complex_Cases-
12-3-13.pdf [https://perma.cc/3QAG-G7HC] [hereinafter J. Robinson’s Briefing Guidelines]; Guidelines 
for Claim Construction Rulings in Patent Cases, U.S. DISTRICT CT. DISTRICT DEL. (Dec. 21, 2010), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Misc/Claim_Construction_Guideline_12-
21-10.pdf [https://perma.cc/Y9ZC-TZKE] [hereinafter J. Robinson’s Claim Construction Guidelines]. 
74 J. Robinson’s Briefing Guidelines, supra note 73, at 2. 
75 Scheduling Order [Patent], U.S. DISTRICT CT. DISTRICT DEL. (Feb. 25, 2014), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Forms/Sched_Order_Patent_Rev02-25-
14.pdf [https://perma.cc/C6RH-5Q79] [hereinafter J. Sleet’s Patent Scheduling Order]. 
76 Id. at 4 (emphasis added). 
77 See, e.g., Special Master Standing Order, U.S. DISTRICT CT. DISTRICT DEL. (June 13, 2011), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Orders/PDF/Special_Masters_Standing 
Order_6-8-11.pdf [https://perma.cc/A8CR-LRZ2] [hereinafter J. Sleet’s Special Master Standing Order]; 
Procedures – Appointment of Special Masters to Hear Discovery Disputes in Intellectual Property Cases, 
U.S. DISTRICT CT. DISTRICT DEL. (Sept. 2004), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Orders/PDF/spmasproc.pdf 
[https://perma.cc/T5CV-KWNY] [hereinafter J. Sleet’s Special Master Procedures]; Panel – Appoint of 
Special Masters to Hear Discovery Disputes in Intellectual Property Cases, U.S. DISTRICT CT. DISTRICT 
DEL. (Sept. 2004), 




¶22  Among Delaware’s four Article III judges, Judge Richard G. Andrews has the fewest 
patent-specific procedures and guidelines.  Like Judge Robinson and Judge Sleet, he has 
only one scheduling order for patent cases.78  Similarly, his patent scheduling order allows 
parties to file case dispositive motions without reference to ANDA cases,79 but his 
scheduling order is the only explicit guideline applicable to patent cases in his courtroom.80  
What is unique about Judge Andrews’s scheduling order is that he has a unique procedure 
for claim construction.81  Instead of having the parties file separate claim construction 
charts and briefs for the Markman hearing, he requires the parties to exchange their 
proposed claim terms for construction, exchange their proposed constructions, confer, and 
file a Joint Claim Construction Chart, as well as a Joint Claim Construction Brief.82      
III. EMPIRICAL STUDY: SUMMARY JUDGMENT PRACTICE IN DELAWARE VS. 
NEW JERSEY 
¶23  Along with the local rules, the local procedures for handling ANDA cases in the 
District of Delaware and the District of New Jersey vary notably.  Specifically, the two 
districts differ significantly in how they handle summary judgment motions in ANDA 
cases.  This article presents an empirical study that compares the summary judgment 
practice in the two districts.  Like most litigation, the majority of ANDA cases end in 
settlement.83  Therefore, the number of final decisions on the merits to evaluate for this 
study was limited.  Nevertheless, the results of this empirical study show the general way 
in which the two districts handle motions for summary judgment and the variance between 
the districts’ practices.  The data also reveals that the four Article III judges in Delaware 
rarely allow parties to ANDA cases to bring motions for summary judgment.  
A.  Data Collection for the Empirical Study 
¶24  This empirical study was conducted by collecting data from ANDA cases filed in the 
Districts of Delaware and New Jersey between 2009 and 2013.  The author searched the 
dockets of the two districts for cases filed during the relevant time period using Bloomberg 
Law’s docket search feature.  The study was limited to ANDA cases filed on or after 
January 1, 2009 through December 31, 2013.  The dockets were searched using the 
keywords “ANDA AND summary judgment” and “Hatch-Waxman AND summary 
judgment.”  The search found every case in those districts where a document on the docket 
 
http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Orders/PDF/spmaspanel.pdf 
[https://perma.cc/4HAX-WBA7] [hereinafter J. Sleet’s Special Masters Panel]. 
78 See Scheduling Order, U.S. DISTRICT CT. DISTRICT DEL. (Apr. 2012), 
http://www.ded.uscourts.gov/sites/default/files/Chambers/RGA/Forms/Rule16_Scheduling_Order-
Patent.pdf [https://perma.cc/SSH5-L8TS] [hereinafter J. Andrews’s Patent Scheduling Order]. 
79 See id. at 6. 
80 See Judge Richard G. Andrews, U.S. DISTRICT CT. DISTRICT DEL., 
http://www.ded.uscourts.gov/judge/judge-richard-g-andrews (last visited Mar. 10, 2016) 
[https://perma.cc/DR7X-JJ9A]. 
81 See J. Andrew’s Patent Scheduling Order, supra note 78, at 3–4. 
82 See id. at 3–5. 
83 See 2014 Patent Litigation Study, supra note 33, at 21. 
Vol. 14:1] Katherine Rhoades 
93 
 
contained the word “summary judgment” and either “ANDA” or “Hatch-Waxman” in its 
title or body.84   
¶25  The author subsequently analyzed every docket sheet within those search parameters 
and recorded whether a motion for summary judgment, request for leave to file a motion 
for summary judgment, or both were filed within each case.85  In analyzing those cases in 
which a party filed a motion for summary judgment or sought leave to file a motion for 
summary judgment, the author also recorded the judge’s decision. 
B.  The Results of the Study  
¶26  The data collected from the empirical study is presented in Table I.  Table I shows 
the number of cases where a party brought at least one motion for summary judgment, the 
number of cases where a motion was granted, and the number of cases where the judge 
issued a summary judgment decision and that decision was case dispositive.  Table I further 
shows the number of cases where a party requested leave to file a motion for summary 
judgment and whether that request was granted.  Table I displays the data from the 
empirical study by district.  The data for the District of Delaware is further broken down 
by judge since the procedures governing ANDA cases in Delaware vary by judge.86  The 
results for the District of New Jersey were not separated by judge because New Jersey has 
six times the number of judges as the District of Delaware and has uniform patent rules 
governing ANDA cases.  Therefore, the author presumed that New Jersey was less likely 
to have wide divergence between judges.  The data presented in Table I was also organized 
into Chart I to compare the summary judgment practice between the two districts.  The data 
for the District of Delaware was further arranged in Chart II to show the variance among 
its four Article III judges.    
TABLE I. SUMMARY JUDGMENT DATA FOR ANDA CASES 2009–201387 
 Delaware New Jersey 
 Stark Robinson Sleet Andrews All Judges All Judges 
Summary Judgment 
Motions 2 1 0 4 7 31 
Granted 
Summary Judgment 
Motions88  1 1 0 2 4 10 
 
84 The author acknowledges that the results are dependent upon the search terms used and Bloomberg 
Law’s algorithm and is cognizant that there may be relevant cases that did not meet the search parameters.  
However, the objective of the empirical study was to compare the general summary judgment practice in 
the two districts in ANDA cases.  Therefore, even if the data is not complete, the results are still useful for 
showing this point.  
85 If an ANDA case was filed before December 31, 2013 but the case had not reached the dispositive 
motion stage, no data for that case was recorded.  
86 See supra Section II(B).  
87 For the data used to compile Table I, see Empirical Study Data, infra Appendix A. 
88 If a motion for summary judgment was not granted, that does not necessarily mean that the 
motion was denied.  The results reflect only those cases where the judge reached a decision on the 
summary judgment motion(s).  There were two summary judgment motions filed in the District of 
Delaware and recorded in Table I—one before Judge Andrews and the other before Judge Stark— that 
were neither granted nor denied.  See Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D. 




Cases Decided at 
Summary Judgment 0 1 0 2 3 1 
Requests for Leave to 
File a Motion for 
Summary Judgment89 2 0 4 4 10 1 
Granted Requests for 
Leave to File Motion 
for Summary 
Judgment90  0 0 0 1 1 1 
 





Del. Apr. 12, 2013) (order granting parties’ joint stipulation of dismissal with prejudice); Novartis Pharm. 
Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. July 7, 2013) (order granting the parties’ joint 
stipulation of noninfringement and dismissing the case). 
 
89 This data includes formal requests for leave as well as letters to judges requesting permission to 
file a motion for summary judgment or to alter their usual practice of not allowing dispositive motions.  
The author notes that there may have been informal requests that were not reflected on the dockets.   
 
90 If a request for leave was not granted, that does not mean that the request was necessarily 
denied.  The results reflect only those cases where the judge reached a decision on the request.  There was 
one request for leave before Judge Andrews that was withdrawn before he rendered a decision.  See 
Novartis Pharm. Corp. v. Noven Pharm. Inc., No. 13-527 (D. Del. Oct. 22, 2014) (notice of withdrawal of 
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CHART II. SUMMARY JUDGMENT DATA IN DELAWARE BY JUDGE 
 
 
¶27  Two things are apparent from the results of the empirical study: (1) the judges in the 
District of Delaware rarely allow parties to bring motions for summary judgment, and (2) 
there appears little uniformity among Delaware’s judges as to whether the motions will be 
allowed. 
C.  Summary Judgment Is Rare in the District of Delaware 
¶28  One thing is apparent from the results of the empirical study: the four judges in the 
District of Delaware entertain few summary judgment motions in ANDA cases.  From 
2009–2013, litigants filed only seven motions for summary judgment before judges in the 
District of Delaware.91  This may be because litigants know Delaware judges rarely 
entertain these motions or have realized that such motions are not successful in ANDA 
cases in the district.  Of those seven motions, four were granted92 and three were case 
 
91 Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; see Motion for Summary 
Judgment of Noninfringement by Upsher-Smith Labs. Inc., Auxilium Pharm. Inc. v. Upsher-Smith Labs. 
Inc., No. 13-148 (D. Del. Apr. 5, 2013); Motion for Summary Judgment of Noninfringement by Alvogen 
Grp. Inc., Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014); Motion 
for Summary Judgment of Invalidity by Mylan Institutional Inc., Spectrum Pharm. Inc. v. InnoPharma Inc., 
No. 12-260 (D. Del. Oct. 17, 2014); Motion for Partial Summary Judgment of Noninfringement by Actavis 
Mid Atlantic LLC, Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D. Del. Mar. 1, 2013); 
Motion for Summary Judgment by Anchen Inc., Shire LLC v. Teva Pharm. USA Inc., No. 10-329 (D. Del. 
June 20, 2012); Motion for Summary Judgment of Invalidity by Sandoz Inc., Wyeth Holdings Corp. v. 
Sandoz Inc., No. 09-955 (D. Del. Feb. 10, 2012); Motion for Summary Judgment of Invalidity by Lupin 
Ltd., Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. Mar. 25, 2011). 

































dispositive.93  In comparison, the District of New Jersey’s judges entertained thirty-one 
motions and granted a third of those motions.94  However, only one of those thirty-one 
motions was case dispositive.95  Since 2009, there have been 678 ANDA cases filed in the 
District of Delaware and 481 filed in the District of New Jersey.96  That means the District 
of New Jersey handles thirty percent fewer ANDA cases than Delaware97 but entertains 
over four times the number of motions for summary judgment.98  And while the District of 
New Jersey entertains over four times the number of summary judgment motions, its judges 
resolved fewer cases at summary judgment than Delaware’s judges between 2009 and 
2013.99 
¶29  In the District of Delaware, parties sometimes seek leave to file a motion for 
summary judgment.  The requests, when made, are rarely granted.  There were ten such 
requests for leave filed between 2009 and 2013,100 but only one of those requests was 
 
motion for summary judgment of noninfringment); Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260 
(D. Del. Aug. 4, 2015) (order granting motions for summary judgment of noninfringement and invalidity); 
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order granting 
defendants’ motion for summary judgment); Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. May 19, 
2011) (order denying defendants’ motion for summary judgment of invalidity and granting plaintiffs’ 
motion for summary judgment of validity).  
93 Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 30, 2013) (final judgment 
of noninfringement); Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260 (D. Del. Aug. 4, 2015) (order 
directing clerk to close the case after holding the patents-in-suit invalid and not infringed); Novartis Pharm. 
Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. July 7, 2014) (final judgment of noninfringement).  
94 Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; see Noven Pharm. v. Watson 
Labs., Inc., No. 11-5997 (D.N.J. Nov. 26, 2013) (order granting defendants’ motion for summary judgment 
of invalidity and noninfringement and denying plaintiff’s cross-motion for summary judgment of validity); 
Shire LLC v. Amneal Pharm., LLC, No. 11-3781 (D.N.J. June 23, 2014) (order granting plaintiffs’ motions 
for summary judgment in part and denying in part and granting defendants’ motions for summary judgment 
in part and denying in part); Gilead Scis., Inc. v. Natco Pharm. Ltd., No. 11-1455 (D.N.J. Dec. 21, 2012) 
(order granting plaintiffs’ motion for summary judgment); Braintree Labs., Inc. v. Novel Labs., Inc., No. 
11-1341 (D.N.J. Jan. 18, 2013) (order granting plaintiff’s motions for summary judgment and denying 
defendant’s motion for summary judgment); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-1241 
(D.N.J. Dec. 16, 2013) (same); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-230 (D.N.J. Dec. 16, 
2013) (same); Janssen Prods., L.P. v. Lupin Ltd., No. 10-5954 (D.N.J. Mar. 12, 2014) (order granting in 
part and denying in part parties’ motions for summary judgment); Merck Sharp & Dohme Corp. v. Mylan 
Pharm. Inc., No. 09-6383 (D.N.J. Aug. 22, 2011) (order granting in part and denying in part plaintiff’s 
motions for summary judgment); Reckitt Benckiser Inc. v. Tris Pharma, Inc., No. 09-3125 (D.N.J. Dec. 21, 
2011) (order granting defendant’s motion for summary judgment); Sunovion Pharm. Inc. v. Teva Pharm. 
USA, Inc., No. 09-1302 (D.N.J. Jan. 1, 2013) (order granting defendants’ motion for summary judgment).   
95 See Shire LLC v. Amneal Pharma., LLC, No. 11-3781 (D.N.J. July 21, 2014) (order of final 
judgment). 
96 Noonan, supra note 5. 
97 See id.  
98 See Summary Judgment Data for ANDA Cases 2009–2013, supra Table I. 
99 See id. 
100 See Letter from Defendants Requesting Summary Judgment Practice, Fresenius Kabi USA, LLC v. 
Watson Labs. Inc., No. 13-1015 (D. Del. Mar. 4, 2014); Letter from Defendants Requesting Summary 
Judgment Practice, Fresenius Kabi USA, LLC v. Dr. Reddy’s Labs. Ltd., No. 13-925 (D. Del. Mar. 4, 
2014); Letter from Defendants Requesting Summary Judgment Practice, Novartis Pharm. Corp. v. Noven 
Pharm. Inc., No. 13-527 (D. Del. Oct. 15, 2014); Motion for Leave to File a Summary Judgment Motion, 
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. May 29, 2014); Letter from 
Defendants Requesting Leave to File a Summary Judgment Motion, Cubist Pharm., Inc. v. Hospira, Inc., 
No. 12-367 (D. Del. Oct. 8, 2013); Letter from Defendants Requesting Leave to File a Summary Judgment 
Motion, Allergan Inc. v. Akorn Inc., No. 11-1270 (D. Del. May 24, 2012); Letter from Defendants 
Requesting Leave to File a Summary Judgment Motion, Galderma Labs. Inc. v. Amneal Pharm. LLC, No. 
11-1106 (D. Del. Apr. 17, 2012); Letter from Defendant Seeking Permission to File a Motion for Summary 
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granted.101  For example, Chief Judge Stark denied every request for leave during that time 
period.102  In fact, Judge Andrews was the only judge to grant a party’s request for leave.103  
In comparison, there was only one request for leave to file a motion for summary judgment 
in New Jersey, and that request was granted.104  This may be because the judges in New 
Jersey regularly entertain motions for summary judgment in ANDA cases, and thus, parties 
need not seek permission before filing.   
D. Delaware’s Practice: Disjunctive or Consistent and Predictable?    
¶30  The results from the empirical study show that the judges in the District of Delaware 
do entertain motions for summary judgment occasionally, but the decision to hear such a 
motion appears discretionary to each individual judge.105  At first glance, the District of 
Delaware’s practice may seem unpredictable and inconsistent.  For example, Judge Sleet’s 
patent scheduling order requires parties to seek permission before filing motions for 
summary judgment,106 but Judge Sleet denied every request between 2009 and 2013.107  In 
comparison, between 2009 and 2013, Chief Judge Stark did not grant a single request for 
leave, yet he entertained motions for summary judgment in two cases where the parties did 
not first request leave to file the motions.108  Similarly, Judge Andrews granted only one 
request for leave109 but heard four motions for summary judgment.110  On the other hand, 
 
Judgment, AbbVie Inc. v. Hospira Inc., No. 11-648 (D. Del. Jan. 4, 2013); Letter from Defendants Seeking 
Permission to File a Motion for Summary Judgment, Endo Pharm. Inc. v. Mylan Techs. Inc., No. 11-220 
(D. Del. Apr. 15, 2013); Letter from Defendant Requesting Leave to File a Motion for Summary Judgment, 
Roche Palo Alto LLC v. Endo Pharm. Inc., No. 10-261 (D. Del. June 4, 2010). 
101 See Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order 
granting defendants’ motion for leave to file a motion for summary judgment).  Again, this study only 
looked at formal requests for leave or requests made through letters written to the judge.  Requests for leave 
can also come through the scheduling order.  See, e.g., AstraZeneca AV v. Aurobindo Pharma Ltd., No. 14-
664 (D. Del. Oct. 17, 2014) (consolidated) (granting a request for leave via the parties’ proposed 
scheduling order).  Requests for leave through the scheduling order were not looked at in this study, so 
there may be additional requests and grants that were made via the Rule 16 conference and scheduling 
order.       
102 See Allergan Inc. v. Akorn Inc., No. 11-1270 (D. Del. June 21, 2012) (denying defendants’ request); 
Galderma Labs. Inc. v. Amneal Pharm. LLC, No. 11-1106 (D. Del. Apr. 23, 2012) (same). 
103 See Novartis Pharm., No. 13-52 (order granting defendants’ motion for leave).  
104 See Sunovion Pharm. Inc. v. Teva Pharm. USA, Inc., No. 09-1302 (D.N.J. Oct. 1, 2011) (order 
granting request for leave to file summary judgment motions). 
105 See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Table I. 
106 See J. Sleet’s Patent Scheduling Order, supra note 75, at 4.  
107 See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Table I; Cubist Pharm., Inc. v. 
Hospira, Inc., No. 12-367 (D. Del. Jan. 15, 2014) (order denying defendant’s letter request to file a motion 
for summary judgment); AbbVie Inc. v. Hospira Inc., No. 11-648 (D. Del. Mar. 25, 2013) (oral order 
denying letter request for permission to file a motion for summary judgment); Endo Pharm. Inc. v. Mylan 
Techs. Inc., No. 11-220 (D. Del. May 3, 2013) (order denying letter request seeking leave to move for 
summary judgment); Roche Palo Alto LLC v. Endo Pharm. Inc., No. 10-261 (D. Del. Feb. 23, 2011) 
(stating that there will be no summary judgment practice during a telephone conference with the parties). 
108 See Motion for Partial Summary Judgment of Noninfringement by Actavis Mid Atlantic LLC, 
Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D. Del. Mar. 1, 2013); Motion for 
Summary Judgment of Invalidity by Lupin Ltd., Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. Mar. 25, 
2011).  The author recognizes that the parties may have requested leave through the Rule 16 conference 
and scheduling order, but no such request was present on the either case’s docket sheet.       
109 See Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order 
granting defendants’ motion for leave to file a motion for summary judgment). 
110 See Motion for Summary Judgment of Noninfringement by Alvogen Grp. Inc., Novartis Pharm. 




in the only case where Judge Robinson granted a party’s request for leave, she also granted 
that same party’s motion for summary judgment.111  The results displayed in Chart II 
further illustrate that the practices in the District of Delaware are “courtroom specific.”112   
¶31  The District of Delaware’s practice may seem inconsistent and discretionary, but 
Delaware’s practice is actually quite uniform.  While each judge has discretion over 
whether he or she will entertain a motion for summary judgment or a request for leave to 
file such a motion in an ANDA case, the four Article III judges are surprisingly consistent 
in how they handle summary judgment motions.  The results of the empirical study show 
that, overall, the District of Delaware’s judges entertain very few requests for leave and 
motions for summary judgment.113  This practice is consistent across each of Delaware’s 
four Article III judges.  Therefore, the District of Delaware’s tendency to exclude summary 
judgment practice in ANDA cases is actually consistent across the district.  This gives 
parties predictability.     
IV. NO NEED FOR DELAWARE TO CHANGE ITS PROCEDURES IN ANDA CASES    
¶32  Notwithstanding the variations among the judges’ standing orders, the investigation 
into the District of Delaware’s practice and the empirical study highlights the remarkable 
consistency between the judges in Delaware in granting—or even hearing—summary 
judgment motions in ANDA cases.  There are certainly differences in the judges’ standing 
orders and summary judgment may not be an option for parties in ANDA cases in the 
District of Delaware, but litigants know what to expect in each judge’s courtroom based 
on their detailed standing orders and overall preference for no summary judgment motion 
practice.  The District of Delaware does not need to adopt uniform local patent rules or 
specific Hatch-Waxman provisions as the District of New Jersey has done.  Delaware could 
be more receptive to summary judgment motions, but its current practice is efficient in 
moving ANDA cases to trial, which are ultimately bench trials before the judge.  However, 
the District of Delaware could benefit by requiring early disclosure of the ANDA in these 
cases.   
A. The Purpose and Benefit of Local Patent Rules 
¶33  Patent litigation imposes a number of additional “substantive, procedural, and 
administrative challenges” on tribunals due to the highly technical and complex nature of 
the subject matter.114  Former Chief Judge Rader of the U.S. Court of Appeals for the 
Federal Circuit acknowledged “that one of the greatest challenges in patent law is ‘the 
 
Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014); Motion for Summary Judgment of 
Invalidity by Mylan Institutional Inc., Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260 (D. Del. Oct. 
17, 2014); Motion for Summary Judgment by Anchen Inc., Shire LLC v. Teva Pharm. USA Inc., No. 10-
329 (D. Del. June 20, 2012); Motion for Summary Judgment of Invalidity by Sandoz Inc., Wyeth Holdings 
Corp. v. Sandoz Inc., No. 09-955 (D. Del. Feb. 10, 2012). 
111 See Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 4, 2013) (order 
granting motion for summary judgment of noninfringment). 
112 See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Chart II. 
113 See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Table I. 
114 Pauline M. Pelletier, The Impact of Local Patent Rules on Rate and Timing of Case Resolution 
Relative to Claim Construction: An Empirical Study of the Past Decade, 8 J. BUS. & TECH. L. 451, 453 
(2013). 
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expense and delay of the litigation system.’”115  However, the complex issues in patent 
litigation can usually be narrowed to a short, critical list of case dispositive issues, such as 
whether a patent claim is valid or whether the ANDA filer’s drug infringes the claim.116  
Thus, narrowing these issues early on in litigation reduces the complexity of the case.117 
¶34  Local patent rules can assist with narrowing complex patent infringement claims.  
Such rules usually require patentees to serve and disclose to the alleged infringers their 
asserted claims and infringement contentions.118  These disclosures are typically in the 
form of charts whereby the patentee compares its patent in detail — “claim-by-claim, 
element-by-element” — with the alleged infringer(s)’s product(s).119  Normal procedural 
rules may be insufficient to handle complex patent litigation cases.  For example, if a 
patentee brings an infringement suit for its complicated patent containing fifty claims, the 
defendant’s attorney—even if very knowledgeable in the specific art—“would have a 
difficult time defending his client if the [patentee’s] attorney only made ‘a short and plain 
statement of the claim showing that the pleader is entitled to relief.’”120  Further, without 
clear and organized contentions presented by the parties, it is difficult for a judge and 
jury121—who do not have a background in the technology—to understand the important 
issues.122 
¶35  Along with reducing the complexity of patent cases, another major benefit of local 
patent rules can be a quicker resolution of patent cases.123  Patent rules can affect the timing 
of a case, as well as the outcome.124  Uniform rules can lead to fairly standard case 
management within a district, relatively predictable case timelines, and overall “increased 
efficiency.”125  
¶36  ANDA cases are unique from other forms of patent litigation.  ANDA litigation 
begins when a generic files a Paragraph IV certification in its ANDA arguing that the patent 
is invalid, not infringed, or otherwise unenforceable.126  The patent holder, usually a brand-
name drug company, can then bring suit against the generic after the generic files the 
Paragraph IV certification because filing a Paragraph IV certification is a statutory-based 
 
115 Id. at 462 (citations omitted). 
116 See id. 
117 Patent litigation issues do not become simple merely by narrowing the issues.  The subject matter 
remains highly technical, though there remain fewer case dispositive issues.  For example, a pharmaceutical 
patent may contain fifty claims, but judgment may turn on whether just one of those claims is valid.  Thus, 
by narrowing the issues in the case to whether that one claim is valid, the litigation becomes more focused. 
118 Megan Woodhouse, Shop ‘Til You Drop: Implementing Federal Rules of Patent Litigation Procedure 
to Wear Out Forum Shopping Patent Plaintiffs, 99 GEO. L.J. 227, 248 (2010). 
119 See id.  The patentee’s chart includes two columns.  Id.  The first column lists the asserted claim of 
the patent and separates the claim’s elements by rows, “and the second column [compares] specific 
information regarding the defendant’s product that allegedly infringes the elements of the [] patent.”  Id.  
Patentees must also provide “the details regarding the legal theories [they] are using to assert the claims in 
the patent.”  Id. 
120 Id. 247–28 (quoting FED. R. CIV. P. 8(a)(2)).  
121 While there are no juries in ANDA cases, there can be juries in other patent litigation suits.  See 
Coggio et al., supra note 42, at 767. 
122 Woodhouse, supra note 118, at 248. 
123 See Pelletier, supra note 114, at 463; Woodhouse, supra note 118, at 252–53.  
124 See Jensen, supra note 47. 
125 Pelletier, supra note 114, at 463.  When case schedules are predictable, attorneys can better estimate 
and stick to their clients’ case budgets.  See Gollwitzer, supra note 47, at 94.  
126 See 2014 Patent Litigation Study, supra note 33, at 20. 




act of infringement.127  Frequently, the critical issue is whether the patent(s) on which the 
generic seeks to market its generic equivalent is valid.128  Additionally, because the Hatch-
Waxman Act requires all Paragraph IV ANDA filers to provide notice to the challenged 
patent holder, which “include[s] a detailed statement of the factual and legal basis” of why 
the applicant believes “that the patent is invalid or will not be infringed,” the ANDA filer 
is not in the same position as an accused infringer in a normal patent infringement action 
before litigation commences.129  Instead, the ANDA filer is well aware of the risks 
associated with filing a Paragraph IV certification before it files the ANDA and has already 
established its noninfringement or invalidity position before the patentee files suit.130  
1. Local Patent Rules Are Not Necessary in Delaware 
¶37  It is no secret that the District of Delaware’s four Article III judges have extensive 
patent experience and are some of the most experienced in the country in handling patent 
infringement cases.131  The District of Delaware leads all other district courts with the most 
patent case filings per judge, which results in an experienced bench.132  In fact, Judge 
Andrews, Judge Robinson, Judge Sleet, and Chief Judge Stark are among the U.S. district 
court judges who hear the most patent cases,133 and they are the four judges that hear the 
most ANDA cases in the country.134  And when it comes to patent litigation, “[e]xperience 
leads to efficiency, uniformity, and better case management.” 135  All four Article III judges 
in the District of Delaware are extremely experienced and knowledgeable in patent issues 
despite the district’s lack of uniform patent rules.  Unlike judges who “lack[] prior patent 
litigation experience [and] would benefit from patent trial rules,”136 Delaware’s judges 
have extensive experience and it may be superfluous for Delaware to adopt uniform local 
patent rules.   
¶38  The District of Delaware’s lack of local patent rules does not seem to have affected 
the district’s case efficiency or time-to-trial.137  Research “suggests that districts with local 
 
127 See 35 U.S.C. § 271(e)(2)(A) (2015); 21 U.S.C. § 355(j)(5)(B)(iii) (2015). 
128 See 2014 Patent Litigation Study, supra note 33, at 20. 
129 21 U.S.C. § 355(j)(2)(B)(iv)(II). 
130 See id. 
131 See Comparison of the Most Popular Patent Venues, supra note 58. 
132 See id.  The most patent cases are filed in the Eastern District of Texas, and the District of Delaware 
has the second most filings.  Patent Litigation Statistics, IP LAW ALERT, 
http://iplawalert.wp.lexblogs.com/wp-content/uploads/sites/242/2014/03/Patent-Litigation-Research.pdf 
(last visited Mar. 13, 2016) [https://perma.cc/4S3D-6V8L].  These two districts “have nearly three times 
the number of patent cases as the third busiest district, the Central District of California.”  Charles H. 
Chevalier et al., New Patent Case Scheduling Order Seeks to Achieve Efficiencies in Delaware, IP LAW 
ALERT (Mar. 26, 2014), http://www.iplawalert.com/2014/03/articles/patent/new-patent-case-scheduling-
order-seeks-to-achieve-efficiencies-in-delaware/ [https://perma.cc/KU4Z-XNGK].  However, the District 
of Delaware has only four district court judges in comparison to eight in the Eastern District of Texas, 
Judges, U.S. DISTRICT CT. E. DISTRICT TEX., http://www.txed.uscourts.gov/page1.shtml?location=info (last 
visited Mar. 13, 2016) [https://perma.cc/99M3-HFND], and therefore has the most patent case filings per 
judge.  
133 See Patent Litigation Statistics, supra note 132; see also 2014 Patent Litigation Study, supra note 33, 
at 22.  
134 Noonan, supra note 5.  
135 Woodhouse, supra note 118, at 252. 
136 Id. at 247. 
137 See 2013 Patent Litigation Study, supra note 45, at 30. 
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patent rules process patent cases faster than districts lacking such rules.”138  However, this 
research is not dispositive.139  Additionally, experienced judges can resolve cases more 
quickly.140  The District of Delaware has an overall faster time-to-trial—time from the day 
the complaint is filed to the first day of trial—than the District of New Jersey for patent 
cases that do not settle.141  While local patent rules can decrease the time-to-trial, 
Delaware’s experienced bench is efficient in resolving patent disputes.    
¶39  Uniform local patent rules could still benefit Delaware’s experienced bench.  
Although the District of Delaware’s judges are among the most knowledgeable in patent 
issues, including ANDA cases, it may appear there is no uniformity among the judges.  
Each judge has different standing orders that apply to cases in his or her courtroom,142 and 
the procedures governing ANDA cases in the District of Delaware are “courtroom specific” 
and vary among the individual judges.143  Uniform local patent rules can increase judicial 
efficiency for inexperienced and experienced judges alike.144  Local patent rules could only 
improve the district’s efficiency in handling patent cases.  However, because the District 
of Delaware has only four Article III judges—all of whom are extremely knowledgeable 
in patent issues—and patent litigation in that district is already more efficient than in other 
districts that have adopted local patent rules, it is probably not necessary for the District of 
Delaware to adopt local patent rules.145 
¶40  Even if the District of Delaware adopted local patent rules, thereby increasing 
uniformity across its bench, that would not create uniformity among all patent litigation, 
or more specifically, among ANDA litigation, in the United States.  While many district 
courts have adopted uniform local patent rules, those rules only apply to that specific 
district.146  Local patent rules vary widely among the twenty-four districts that have 
formally adopted them.147  This disunity can “yield legal clutter, undue complexity, and 
unfairness” across patent litigation.148  
 
138 Gollwitzer, supra note 47, at 95 (discussing a study by LegalMetric that found “in districts adopting 
local patent rules, the average time patent cases were pending decreased by 2 1/2 months when compared 
to the average time pending prior to adopting the rules”). 
139 See id. (noting that “[t]he two most notable patent ‘rocket-dockets,’ the Eastern District of Virginia 
and the Western District of Wisconsin, have not adopted local patent rules”).  
140 See Woodhouse, supra note 118, at 244 (“Experienced judges would be more familiar with the stages 
of patent litigation, and trials would be faster.”). 
141 See 2013 Patent Litigation Study, supra note 45, at 30.  These statistics are not specific to ANDA 
litigation but instead are general statistics of patent litigation in those districts.  See id.  
142 See Standing Orders, supra note 55. 
143 See e.g., Chief J. Stark’s ANDA Patent Scheduling Order, supra note 61; J. Robinson’s Patent 
Scheduling Order, supra note 61; J. Sleet’s Patent Scheduling Order, supra note 75; J. Andrews’s Patent 
Scheduling Order, supra note 78. 
144 See Woodhouse, supra note 118, at 252–53.  
145 Adding local patent rules certainly would not hurt the district, but the district may not see much 
benefit from adopting such rules.  Local patent rules are designed to help judges inexperienced in patent 
issues, see id., and that certainly is not the case on the District of Delaware’s bench.  
146 See Pelletier, supra note 114, at 464.   
147 See id.  
148 Id. 




2. The Benefits of Early Disclosure in ANDA Cases 
¶41  While the District of Delaware does not need local patent rules, it could consider 
requiring generics to disclose the ANDA submitted to the FDA earlier in the litigation.  
The Hatch-Waxman Act only requires that the ANDA filer give notice to the patentee when 
it files a Paragraph IV certification in its ANDA.149  This notice does not require the generic 
to disclose the contents of its ANDA, but need only “include a detailed statement of the 
factual and legal basis” of why the applicant believes “that the patent is invalid or will not 
be infringed.”150  Patent rules that require parties to make disclosures early on in the 
litigation “enhances the transparency, organization, and accuracy of the patent litigation 
process.”151  This is especially true in ANDA cases where the generic has already submitted 
a Paragraph IV certification to the FDA in its ANDA.   
¶42  Prior to litigation, as required under the Hatch-Waxman Act, the ANDA filer has 
already made certain contentions to the FDA in its Paragraph IV certification as to why the 
patent is invalid or not infringed152 and has provided notice to the patent holder of its factual 
and legal theories behind its Paragraph IV certification.153  The patent holder has forty-five 
days to review the Paragraph IV certification before initiating an infringement suit.154  This 
puts the ANDA filer in a unique position before litigation commences and even before 
filing its ANDA.  By filing a Paragraph IV certification, the generic essentially asserts: (1) 
that it has reviewed the patent(s), (2) that it believes the patent(s) is invalid or not infringed 
by the generic’s drug, and (3) that it has researched the legal theories to support its position.  
Requiring the ANDA filer to disclose the ANDA earlier in litigation, such as when it files 
its answer, could increase transparency in the litigation since the ANDA filer is uniquely 
situated and has already provided the FDA with substantially relevant information in its 
ANDA, specifically, in its Paragraph IV certification. 
¶43  The District of New Jersey has recognized this unique position ANDA litigants stand 
in before litigation commences and has adopted unique early disclosure requirements that 
apply specifically to ANDA cases.  In 2010, New Jersey amended its local patent rules to 
include specific disclosure provisions that govern all patents challenged by a Paragraph IV 
certification in cases arising under the Hatch-Waxman Act.155  The amendments impose 
certain early disclosure requirements on both the party alleging patent infringement and 
the ANDA filer.156  Of particular importance is the amendment relating to early disclosure 
of the ANDA.157  The ANDA filer must produce the complete ANDA with its answer or 
motion in response to the complaint,158 disclose its noninfringement and invalidity 
contentions for any patents referred to in its Paragraph IV certification within fourteen days 
 
149 See 21 U.S.C. § 355(j)(2)(B)(iv)(II) (2015).  
150 Id.  
151 See Woodhouse, supra note 118, at 248. 
152 See 21 U.S.C. § 355(j)(2)(A)(vii)(IV). 
153 See id. § 355(j)(2)(B)(iv)(II). 
154 See id. § 355(j)(5)(B)(iii). 
155 See D.N.J. L. PAT. R. 3.6. 
156 See id. 
157 See id. 3.6(a). 
158 See id. 3.6(a) (“On the date a party answers, moves, or otherwise responds, each party who is an 
ANDA filer shall produce to each party asserting patent infringement the entire Abbreviated New Drug 
Application or New Drug Application that is the basis of the case in question.”). 
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after the initial Scheduling Conference,159 produce all FDA communications pertaining to 
the ANDA, and inform the FDA of any injunctions and motions in the case.160   
¶44  Due to the unique information the defendant in ANDA litigation acquires before 
commencement of the suit, it is fair to require that party—the ANDA filer—to make these 
early disclosures to the plaintiff.  The ANDA filer has already made contentions in its 
Paragraph IV certification and argued why the patent is invalid or not infringed,161 and the 
patentee has decided to refute those contentions.  Like the District of New Jersey, the 
District of Delaware should consider adopting similar early disclosure rules that require 
the ANDA filer to (1) produce the complete ANDA with is answer or motion in response 
to the complaint, (2) disclose its invalidity and non-infringement contentions first, and (3) 
produce all FDA communications.162   
B. Is Summary Judgment Proper in ANDA Litigation? 
¶45  Along with the District of Delaware’s predictable procedure governing ANDA cases, 
the district’s summary judgment practice is efficient and consistent with the Hatch-
Waxman’s purpose and policies.  The District of Delaware rarely allows parties to bring a 
summary judgment motion in ANDA cases.  While the Federal Rules of Civil Procedure 
explicitly permits parties to move for summary judgment,163 there is usually a question of 
fact in ANDA cases that should be decided at trial, not at summary judgment.164   
1. Summary Judgment Motions Are Not Necessary in ANDA Cases 
¶46  Summary judgment motions are proper when “the movant shows that there is no 
genuine dispute as to any material fact.”165  Patent cases frequently involve a disagreement 
over the facts, which is why “[i]t can be a significant waste of time and money to bring a 
 
159 See id. 3.6(c) (“Not more than 14 days after the initial Scheduling Conference, each party opposing 
an assertion of patent infringement shall provide to each party asserting patent infringement the written 
basis for its ‘Invalidity Contentions,’ for all patents referred to in the opposing party’s Paragraph IV 
Certification . . . .”); id. 3.6(e) (“Not more than 14 days after the initial Scheduling Conference, each party 
opposing an assertion of patent infringement shall provide to each party asserting patent infringement the 
written basis for its ‘Non-Infringement Contentions,’ for any patents referred to in the opposing party’s 
Paragraph IV Certification which shall include a claim chart identifying each claim at issue in the case and 
each limitation of each claim at issue.”).  
160 See id. 3.6(j) (“Each party that has an ANDA application pending with the Food and Drug 
Administration (“FDA”) that is the basis of the pending case shall: (1) notify the FDA of any and all 
motions for injunctive relief no later than three business days after the date on which such a motion is filed; 
and (2) provide a copy of all correspondence between itself and the FDA pertaining to the ANDA 
application to each party asserting infringement . . . .”). 
161 See 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2015); see also Comparison of the Most Popular Patent 
Venues, supra note 58 (recognizing that “[b]ecause of the triggers built into the [A]ct, . . . the potential 
defendant knows the patents that will be asserted, the identity of the plaintiff, and the time frame for filing 
the complaint”).  
162 This would benefit the patentee because he would receive the ANDA filer’s ANDA and 
noninfringement and invalidity contentions before having to narrow his claims asserted and infringement 
contentions.  
163 See FED. R. CIV. P. 56.  
164 Sara Stefanini, Judges’ Top Four Pet Peeves in Patent Litigation, LAW360 (May 1, 2008), 
http://www.law360.com/articles/54905/judges-top-four-pet-peeves-in-patent-litigation 
[https://perma.cc/7XWF-FT2Q]. 
165 FED. R. CIV. P. 56(a). 




summary judgment motion.”166  Former Judge Joseph J. Farnan of the District of Delaware 
believes 90–95% of the time there is a dispute of facts, and thus summary judgment is 
improper in ANDA cases.167  Delaware’s Judge Sleet has stated that summary judgment 
motions are unnecessary in ANDA cases, explaining that both parties usually “have experts 
who are ready, willing and able to come to court and dispute the facts . . . .”168  He has 
asserted that in ANDA cases, a generic is usually attacking a patent for invalidly or 
noninfringement, which almost always involves a dispute of facts.169  Judge Sleet believes 
ANDA cases are more effectively decided after hearing all the arguments, rather than at 
summary judgment.170  Since the resolution of many patent cases turns on a question of 
fact, summary judgment may be unnecessary in most ANDA cases.   
¶47  The data from the empirical study is illustrative of how few ANDA cases are resolved 
at summary judgment.  From 2009–2013, the District of New Jersey entertained thirty-one 
motions for summary judgment and granted ten of those motions.171  Two-thirds of those 
motions were denied, and only one of those thirty-one motions was case dispositive.172  
That means that in the cases where a party moved for summary judgment in the District of 
New Jersey, ninety-seven percent of those cases were not resolved at summary judgment 
and continued towards trial.  In comparison, the District of Delaware entertained two-thirds 
 
166 Stefanini, supra note 164 (quoting Delaware’s former Chief Judge Sleet). 
167 See id. 
168 Id. 
169 See id. 
170 See id.  Judge Sleet’s procedures reflect his viewpoint on summary judgment motions in ANDA 
cases.  For example, he requires parties to ask permission before filing a motion for summary judgment 
“[t]o clamp down on filing that will undoubtedly lack merit in [ANDA] cases . . . .”  Id.; see J. Sleet’s 
Patent Scheduling Order, supra note 75.  When a party seeks permission, Judge Sleet allows both parties to 
argue their positions to him via teleconference.  See Stefanini, supra note 164.  However, he has started 
taking the teleconferences off the case schedule and simply denying the requests generally because the facts 
are usually disputed.  See id.   
171 See Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; Noven Pharm. v. Watson 
Labs., Inc., No. 11-5997 (D.N.J. Nov. 26, 2013) (order granting defendants’ motion for summary judgment 
of invalidity and noninfringement and denying plaintiff’s cross-motion for summary judgment of validity); 
Shire LLC v. Amneal Pharm., LLC, No. 11-3781 (D.N.J. June 23, 2014) (order granting plaintiffs’ motions 
for summary judgment in part and denying in part and granting defendants’ motions for summary judgment 
in part and denying in part); Gilead Scis., Inc. v. Natco Pharm. Ltd., No. 11-1455 (D.N.J. Dec. 21, 2012) 
(order granting plaintiffs’ motion for summary judgment); Braintree Labs., Inc. v. Novel Labs., Inc., No. 
11-1341 (D.N.J. Jan. 18, 2013) (order granting plaintiff’s motions for summary judgment and denying 
defendant’s motion for summary judgment); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-1241 
(D.N.J. Dec. 16, 2013) (same); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-230 (D.N.J. Dec. 16, 
2013) (same); Janssen Prods., L.P. v. Lupin Ltd., No. 10-5954 (D.N.J. Mar. 12, 2014) (order granting in 
part and denying in part parties’ motions for summary judgment); Merck Sharp & Dohme Corp. v. Mylan 
Pharm. Inc., No. 09-6383 (D.N.J. Aug. 22, 2011) (order granting in part and denying in part plaintiff’s 
motions for summary judgment); Reckitt Benckiser Inc. v. Tris Pharma, Inc., No. 09-3125 (D.N.J. Dec. 21, 
2011) (order granting defendant’s motion for summary judgment); Sunovion Pharm. Inc. v. Teva Pharm. 
USA, Inc., No. 09-1302 (D.N.J. Jan. 1, 2013) (order granting defendants’ motion for summary judgment).   
172 See Shire LLC v. Amneal Pharma., LLC, No. 11-3781 (D.N.J. July 21, 2014) (order of final 
judgment). 
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fewer summary judgment motions than New Jersey173 but resolved three times the number 
of cases at summary judgment.174   
¶48  If a case ultimately involves a question of fact, the case proceeds more quickly to 
trial by skipping the summary judgment stage.  When a party or parties move for summary 
judgment, there are usually lengthy motions and briefing by both parties on the issues.175  
This is burdensome on litigants and the court—in terms of resources, cost, and time—if 
the case ultimately comes down to a question of fact that must be decided at trial.176  In 
other patent litigation disputes, parties may see summary judgment as the last opportunity 
to have the judge decide and resolve the case before it goes to an unpredictable jury.177  
However, since ANDA cases are bench trials, the judge ultimately decides all issues at 
trial.  The risk of leaving those issues to an unpredictable jury if the case is not resolved at 
summary judgment is not present in ANDA cases.  If the judge is going to decide the case 
anyway, then why not skip the lengthy summary judgment briefing and just have a trial?   
¶49  The District of Delaware does not entertain many motions for summary judgment, 
but that district does have an overall faster time-to-trial than the District of New Jersey in 
patent litigation.178  When Delaware’s four Article III judges skip the summary judgment 
stage in ANDA cases altogether, the court does not waste time and resources on hearing 
issues that the judge will ultimately need to decide at trial.  Further, Delaware’s bench is 
experienced and knowledgeable in patent issues, and specifically in ANDA issues, and 
those judges are the ultimate decision makers at trial.179  The District of Delaware’s 
summary judgment practice in ANDA cases may be more efficient because then the judges 
 
173 See Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; Motion for Summary 
Judgment of Noninfringement by Upsher-Smith Labs. Inc., Auxilium Pharm. Inc. v. Upsher-Smith Labs. 
Inc., No. 13-148 (D. Del. Apr. 5, 2013); Motion for Summary Judgment of Noninfringement by Alvogen 
Grp. Inc., Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014); Motion 
for Summary Judgment of Invalidity by Mylan Institutional Inc., Spectrum Pharm. Inc. v. InnoPharma Inc., 
No. 12-260 (D. Del. Oct. 17, 2014); Motion for Partial Summary Judgment of Noninfringement by Actavis 
Mid Atlantic LLC, Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D. Del. Mar. 1, 2013); 
Motion for Summary Judgment by Anchen Inc., Shire LLC v. Teva Pharm. USA Inc., No. 10-329 (D. Del. 
June 20, 2012); Motion for Summary Judgment of Invalidity by Sandoz Inc., Wyeth Holdings Corp. v. 
Sandoz Inc., No. 09-955 (D. Del. Feb. 10, 2012); Motion for Summary Judgment of Invalidity by Lupin 
Ltd., Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. Mar. 25, 2011). 
174 See Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 30, 2013) (final 
judgment of noninfringement); Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260 (D. Del. Aug. 4, 
2015) (order directing clerk to close the case after holding the patents-in-suit invalid and not infringed); 
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. July 7, 2014) (final judgment of 
noninfringement).  
175 See D. Theodore Rave, Questioning the Efficiency of Summary Judgment, 81 N.Y.U. L. REV. 875, 
894 (2006) (discussing how “the parties have an incentive to engage the merits of the case with full briefing 
and presentation of evidence—in essence, a dress rehearsal of the trial”). 
176 See id. at 876 (“Modern summary judgment, however, is a frequently used motion that is costly to 
oppose and, if not granted often enough, may be a net drain on society.”) 
177 See Jennifer F. Miller, Should Juries Hear Complex Patent Cases?, 4 DUKE L. & TECH. REV. 1, 32 
(2004) (discussing the concerns that decisions by juries in complex patent cases “are arbitrary, 
unpredictable, and based on considerations other than the relevant law”); but see Michael J. Mazzeo et al., 
Explaining the “Unpredictable”: An Empirical Analysis of U.S. Patent Infringement Awards, 35 INT’L 
REV. L. & ECON. 58, 69 (presenting an empirical study showing the fear and concern of unpredictable 
patent infringement awards by juries may be unfounded).  
178 See 2013 Patent Litigation Study, supra note 45, at 30.   
179 See Comparison of the Most Popular Patent Venues, supra note 58; see also Patent Litigation 
Statistics, supra note 132; Chevalier et al., supra note 132. 




do not waste time hearing and ruling on ultimately pointless summary judgment motions 
that they will ultimately have to decide at trial.  
¶50  However, summary judgment can be practical in some ANDA cases.  While Hatch-
Waxman cases commonly involve questions of fact, there are situations in which there is 
no dispute of fact.  Of the seven motions for summary judgment filed between 2009 and 
2013 in the District of Delaware, over half of those motions were granted.180  Those 
motions could not have been granted if there was a “genuine dispute as to any material 
fact.”181 
2. Delaware’s Practice Is Consistent with the Purpose of the Hatch-Waxman Act 
¶51  The District of Delaware’s practice does not undermine the goal of the Hatch-
Waxman Act: to get non-infringing, low-cost generic equivalents on the market faster.182  
Commencement of ANDA litigation halts the FDA’s approval process until resolution of 
the case, and this stay can last up to thirty months.183  With little to no chance of being able 
to bring a summary judgment motion and dispose of the case before trial, it may seem like 
the District of Delaware’s practice is contrary to the purpose of the Hatch-Waxman Act.  
However, bypassing the summary judgment stage for ANDA cases may increase case 
efficiency and quicken the time-to-trial if most ANDA cases ultimately come down to a 
question of fact.  When ANDA litigation is resolved more quickly, the generic drugs 
subject to litigation are put in the hands of American consumers more quickly.  
CONCLUSION 
¶52  ANDA litigation is on the rise.  The number of ANDA cases filed increases each 
year,184 and “the number of court decisions from ANDA litigation has grown substantially 
. . . .”185  Since the District of Delaware hears the most ANDA cases of any district court, 
its local rules and summary judgment practice affects a substantial amount of ANDA 
litigation.  Thus, the District of Delaware’s procedures can affect more than just the ANDA 
parties before the court; it can have a dramatic effect on the entire pharmaceutical industry.  
 
180 See Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 4, 2013) (order 
granting motion for summary judgment of noninfringment); Spectrum Pharm. Inc. v. InnoPharma Inc., No. 
12-260 (D. Del. Aug. 4, 2015) (order granting motions for summary judgment of noninfringement and 
invalidity); Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order 
granting defendants’ motion for summary judgment); Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. May 
19, 2011) (order denying defendants’ motion for summary judgment of invalidity and granting plaintiffs’ 
motion for summary judgment of validity). 
181 See FED. R. CIV. P. 56(a). 
182 See H.R. REP. NO. 98–857, pt. 1, at 14 (1984) (“The purpose of Title I of the bill is to make available 
more low cost generic drugs by establishing a generic drug approval procedure for pioneer drugs first 
approved after 1962.”); Avery, supra note 8, at 172. 
183 See 21 U.S.C. § 355(j)(5)(B)(iii) (2015). 
184 See Howard, supra note 5, at 13 (noting that “ANDA case filings have risen slightly in 2014”).  This 
trend is “consistent with the upward trend of overall patent litigation . . . .”  2014 Patent Litigation Study, 
supra note 33, at 20.  
185 2014 Patent Litigation Study, supra note 33, at 20.  Courts handed down an average of eighteen 
ANDA decisions per year from 2010 to 2013 as compared to only eight decisions per year from 2005 to 
2009.  Id.  That is a 225% increase in decisions in just four years!  See id.  
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The district’s procedures and summary judgment practice does not delay consumer access 
to affordable generic drugs.     
¶53  The District of Delaware does not need to adopt local patent rules because its four 
Article III judges are already knowledgeable and efficient in handling ANDA cases.  While 
procedures governing ANDA cases vary between Delaware’s four Article III judges, once 
a litigant knows which judge his or her case is before, the case schedule is predictable.  
However, due to the unique information the defendant in ANDA litigation acquires before 
litigation commences, the District of Delaware could consider adopting early disclosure 
provisions that require that party—the ANDA filer—to (1) produce the complete ANDA 
with is answer or motion in response to the complaint, (2) disclose its invalidity and 
noninfringement contentions first, and (3) produce all FDA communications. 
¶54  The District of Delaware should continue with its practice of only hearing summary 
judgment motions in the exceptional case because most ANDA cases involve questions of 
fact.  If a party brings a summary judgment motion, it can be a waste of court resources 
and time when the motion is eventually denied and the case progresses towards trial.  By 
skipping summary judgment, ANDA cases proceed more quickly to trial where ultimately 
a judge, and not a jury, will decide the issues.  The District of Delaware’s judges are 
efficient in handling and resolving ANDA cases, so this practice does not keep those low-
cost alternatives off the shelf and out of reach of American consumers. 
 
 




APPENDIX A: Empirical Study Data 
 
Table II.  Delaware Cases Used in the Empirical Study 
Parties Docket Number Date Filed 
Fresenius Kabi USA LLC v. Watson Labs. Inc. No. 13-1015 June 6, 2013 
Fresenius Kabi USA LLC v. Dr. Reddy’s Labs. Ltd. No. 13-925 May 23, 2013 
Novartis Pharm. Corp. v. Noven Pharm. Inc. No. 13-527 Apr. 3, 2013 
Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc. No. 13-148 Jan. 28, 2013 
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc. No. 13-52 Jan. 4, 2013 
Cubist Pharm. Inc. v. Hospira Inc. No. 12-367 Mar. 21, 2012 
Spectrum Pharm. Inc. v. InnoPharma Inc. No. 12-260 Mar. 2, 2012 
Allergan Inc. v. Akorn Inc. No. 11-1270 Dec. 21, 2011 
Galderma Labs. Inc. v. Amneal Pharm. LLC No. 11-1106 Nov. 8, 2011 
AbbVie Inc. v. Hospira Inc. No. 11-648 July 21, 2011 
Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC No. 11-409 May 11, 2011 
Abbott Prods. Inc. v. Teva Pharm. USA Inc. No. 11-384 Apr. 29, 2011 
Endo Pharm. Inc. v. Mylan Tech. Inc. No. 11-220 Mar. 14, 2011 
Shire LLC v. Teva Pharm. USA Inc. No. 10-329 Apr. 22, 2010 
Wyeth Holdings Corp. v. Sandoz Inc. No. 09-955 Dec. 11, 2009 
Roche Palo Alto LLC v. Endo Pharm. Inc. No. 10-261 Mar. 31, 2009 
Abbott Labs. v. Lupin Ltd. No. 09-152 Mar. 6, 2009 
 
Table III. New Jersey Cases Used in the Empirical Study 
Parties Docket Number Date Filed 
United Therapeutics Corp. v. Sandoz, Inc. No. 13-316 Jan. 16, 2013 
AstraZeneca AB v. Dr. Reddy’s Labs., Inc.  No. 13-91 Jan. 4, 2014 
Auxilium Pharm., Inc. v. Watson Labs., Inc. No. 12-3084 May 23, 2012 
Warner Chilcott Co. v. Amneal Pharm., LLC No. 12-2928 May 16, 2012 
United Therapeutics Corp. v. Sandoz, Inc. No. 12-1617 Mar. 14, 2012 
Shire LLC v. Watson Labs. Inc. No. 12-83 Jan. 5, 2012 
Santarus, Inc. v. Zydus Pharm. (USA) Inc. No. 11-7441 Dec. 21, 2011 
MSD Consumer Prods., Inc. v. Zydus Pharm. (USA) Inc. No. 11-7437 Dec. 21, 2011 
Noven Pharm. v. Watson Labs., Inc. No. 11-5997 Oct. 13, 2011 
Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd. No. 11-3962 July 8, 2011 
Shire LLC v. Amneal Pharm., LLC No. 11-3781 June 30, 2011 
Hoffmann-La Roche Inc. v. Teva Pharm. USA, Inc. No. 11-3635 June 23, 2011 
The Medicines Co. v. Dr. Reddy’s Labs. Ltd. No. 11-2456 Apr. 28, 2011 
AstraZeneca AB v. Dr. Reddy’s Labs. Inc. No. 11-2317 Apr. 21, 2011 
Gilead Scis., Inc. v. Natco Pharma Ltd. No. 11-1455 Mar. 15, 2011 
Braintree Labs., Inc. v. Novel Labs., Inc. No. 11-1341 Mar. 9, 2011 
Prometheus Labs. Inc. v. Roxane Labs., Inc. No. 11-1241 Mar. 4, 2011 
Prometheus Labs. Inc. v. Roxane Labs., Inc. No. 11-230 Jan. 14, 2011 
Janssen Prods., L.P. v. Lupin Ltd. No. 10-5954 Nov. 15, 2010 
Abbott Labs. v. Lupin Ltd. No. 10-1578 Mar. 26, 2010 
Teva Women’s Health, Inc. v. Mylan Pharm., Inc. No. 10-1234 Mar. 9, 2010 
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Graceway Pharm., LLC v. Perrigo Co. No. 10-937 Feb. 23, 2010 
Teva Women’s Health, Inc. v. Lupin, Ltd. No. 10-80 Jan. 6, 2010 
Merck Sharp & Dohme Corp. v. Mylan Pharm. Inc. No. 09-6383 Dec. 16, 2009 
Merck Sharp & Dohme Corp. v. Apotex Inc. No. 09-6373 Dec. 18, 2009 
Hospira, Inc. v. Sandoz Int’l GmbH No. 09-4591 Sept. 4, 2009 
Reckitt Benckiser Inc. v. Tris Pharma, Inc. No. 09-3125 June 26, 2009 
Hoffmann-La Roche Inc. v. Mylan Inc. No. 09-1692  Apr. 8, 2009 
Sunovion Pharm. Inc. v. Teva Pharm. USA, Inc. No. 09-1302 May 20, 2009 
Merck & Co., Inc. v. Sandoz Inc.  No. 09-890 Feb. 27, 2009 
Dr. Reddy’s Labs., Ltd. v. Eli Lilly & Co. No. 09-192 Jan. 8, 2009 
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